62 results about "Disease/disorder" patented technology

The method for genome analysis translates the clinical findings in the patient into a comprehensive test order for genes that can be causative of the patient's illness, delimits analysis of variants identified in the patient's genome to those that are “on target” for the patient's illness, and provides clinical annotation of the likely causative variants for inclusion in a variant warehouse that is updated as a result of each sample that is analyzed and that, in turn, provides a source of additional annotation for variants. The method uses a genome sequence having the steps of entering at least one clinical feature of a patient by an end-user, assigning a weighted value to the term based on the probability of the presence of the term, mapping the term to at least one disease by accessing a knowledge base containing a plurality of data sets, wherein the data sets are made up of associations between (i) clinical features and diseases, (ii) diseases and genes, (iii) genes and genetic variants, and (iv) diseases and gene variants, assigning a truth value to each of the mapped terms based on the associated data sets and the weighted value, to provide a list of results of possible diagnoses prioritized based on the truth values, with continuous adjustment of the weightings of associations in the knowledge base based on updating of each discovered diagnosis and attendant clinical features, genes and gene variants. This method can be performed in fifty hours or twenty-four hours or less.

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and / or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and / or 3) comprises toxin effectors which retain toxin functions.

The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorders, diseases, or conditions, and improving recoveries and outcomes of orthopedic procedures or surgeries.

The present invention describes compositions of thymus derived peptides and uses therefore in diagnostic methods and for the treatment of diseases associated with reduced T helper cell counts, diseases such as infection, e.g., HIV infection and other viral infections, parasitic, and bacterial infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, rheumatoid arthritis, Alzheimer's disease, asthma, allergy, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease / irritable bowel syndrome, Crohn's disease, Psoriasis, Chronic obstructive pulmonary disease, Systemic lupus erythematosus, transplant rejection and cancer.

The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam. A process for preparing the dosage form is also provided

The invention relates to a doctor-patient matching method based on a Bayesian network, and the method comprises the steps: S1, collecting electronic medical record data, determining disease and symptom nodes and values thereof, and enabling the disease and symptom nodes to serve as training set data; S2, constructing a disease-disease / disease-symptom self-interaction matrix, and taking the disease-disease / disease-symptom self-interaction matrix as a constraint of a Bayesian network; S3, constructing a Bayesian network model, and performing structure learning and parameter learning; S4, inputting the disease into the Bayesian network pre-diagnosis model by the patient to obtain all possible disease combinations for calculating the complication of the main disease and the complication; S5, calculating a matching index of doctors and patients; S6, constructing a doctor recommendation model based on the matching index of the doctors and the patients; and S7, obtaining the optimal allocation of the patients and the doctors according to the preference index of the patient. According to the invention, doctor-patient matching is carried out by combining the pre-diagnosis result, the doctorspecialty, the doctor workload and the patient preference, and the defect that the current doctor-patient matching technology is not accurate enough is solved.

The system disclosed allows a user to specify an illness, disease, or health condition, mental or physical or otherwise, and interconnect with other users having similar diagnoses, symptoms, conditions, complications, treatments, or otherwise. The patient user may be connected to a caregiver who links into the system to connect with other caregivers as well. The social network is a health web designed to interconnect patients, friends, families, doctors or others who seek personalized medical information pertaining to the experiences of others. The system allows an interconnection of patients who want to correspond as to symptoms and treatments, and / or for medical professionals who seek to expand their global knowledge base as to collegial networks for diagnosis, treatment, and real-time evaluation. The social network provides a global interface, connected via mobile device, remotely for medical treatment globally, from the latest innovations in medicine to the remote locations of the world.

The invention relates to a medicament for treating or preventing coronary disease, angor pectoris, myocardial infarction, arrhythmia, ischemic brain disease, cerebral thrombosis, cerebral hemorrhage and sequelae thereof, vascular dementia and peripheral circulation disturbance disease, including various artery occlusions, vasculitis, and microcirculatory disturbance caused by diabetes mellitus, high blood pressure, hyperlipidemia and hyperviscosity as well as refractory neck syndrome, vertebrobasilar artery insufficiency and other ischemic diseases accompanying with microcirculatory disturbance, namely, a scutellarin derivative and preparation and application thereof. The derivative has high storing stability, and is suitable for preparing a medicament for treating or preventing heart cerebrovascular diseases.

The system disclosed allows a user to specify an illness, disease, or health condition, mental or physical or otherwise, and interconnect with other users having similar diagnoses, symptoms, conditions, complications, treatments, or otherwise. The patient user may be connected to a caregiver who links into the system to connect with other caregivers as well. The social network is a health web designed to interconnect patients, friends, families, doctors or others who seek personalized medical information pertaining to the experiences of others. The system allows an interconnection of patients who want to correspond as to symptoms and treatments, and / or for medical professionals who seek to expand their global knowledge base as to collegial networks for diagnosis, treatment, and real-time evaluation. The social network provides a global interface, connected via mobile device, remotely for medical treatment globally, from the latest innovations in medicine to the remote locations of the world.

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions that respond favorably to PTPN1 or PTPN2 inhibitor treatment, such as cancer or metabolic diseases.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and / or prostaglandin levels include 15-PGDH inhibitors described herein.

The invention relates to the treatment or prevention of an inflammatory skin disease, disorder or condition, by modulating a protein that is normally regulated by caspase-8 in the skin or by increasing caspase-8 activity or level in the skin. Another aspect of the invention relates to methods for diagnosing an inflammatory skin disease, disorder or condition or a predisposition to develop said disease disorder or condition in an individual. Further aspects of the invention relate to methods for identifying target proteins involved in the course or pathology of an inflammatory skin disease, disorder or condition and to methods of screening a candidate compound for treating said disease, disorder or condition. In particular, the invention relates to inflammatory skin diseases such as atopic dermatitis and psoriasis.

The invention discloses a drug relocation method and system based on heterogeneous knowledge and structure fusion, and belongs to the technical field of medical care informatics. The method comprises the following steps: constructing a biomedical domain knowledge heterogeneous graph; generating disease knowledge embedding and drug knowledge embedding corresponding to a target drug-disease pair based on the biomedical domain knowledge heterogeneous graph; generating disease structure embedding and drug structure embedding corresponding to the target drug-disease pair by constructing a drug-drug similarity network, a disease-disease similarity network and a drug-disease association network; and based on disease knowledge embedding, drug knowledge embedding, disease structure embedding and drug structure embedding, obtaining a drug relocation result. According to the method, complex biological network characteristics are accurately captured and complex entity information is finely modeled through an innovative drug relocation model, so that accurate drug relocation is realized.

Provided herein are methods and compositions for treating kidney-related diseases disorders, and complications, such as Berger's disease and for preventing transplant rejections. For example, the present disclosure describes methods of improving transplanted kidney function in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds CD40 ligand.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a lipoxygenase inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and / or to prevent or treat metastasis.

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

The present invention relates to a small molecule polypeptide in HD treatment medicine and application thereof, the amino acid sequence of the small molecule polypeptide is shown in SEQ ID No.1. The invention also provides the application of the small molecule polypeptide. The present invention designs a small molecule polypeptide DH1 through the research on the translocation mechanism and function of HSF1. The polypeptide inhibits the mitochondrial translocation of HSF1, weakens the fragmentation of mitochondria, increases the expression of mitochondrial DNA, and then achieves the purpose of protecting neurons and improving the disease process of HD, and provides a new target for HD treatment.

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and / or hydrate, and / or cocrystal, and / or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

A pharmaceutical composition comprising a microbubble / microdroplet cluster composition for use in a method of treatment of diseases, disorders, or injuries of the central nervous system (CNS) is provi

The present disclosure provides oligonucleotides, methods, and compositions for degrading RNA via the lysosomal pathway. Also contemplated are oligonucleotides, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with EXOC2, Ku80, and Task1 in a subject in need thereof.

To provide a AI inquiry device, a AI inquiry method, and a program capable of reducing a burden on a patient during AI inquiry.SOLUTION: The AI inquiry device includes an image inputting part, a disease candidate estimating part, and a disease estimating part. The image input unit receives an input of a face image of a patient. The disease candidate estimation unit extracts symptoms of the patient from the face image of the patient to estimate disease candidates of the patient based on the symptoms of the patient by using the image recognizing AI model. The disease estimation unit uses the interactive AI model to output a question to the subject, receive an input of a response of the subject to the question, and estimate a disease of the subject from candidates for the disease of the subject based on the response of the subject.SELECTED DRAWING: Figure 2

Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and / or preventing diseases, disorders, and / or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and / or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.